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ABSTRACT 
The field of multiple sclerosis (MS) is in need of a consistent method of measuring smoking to 
examine its role in disease risk and severity.  A pilot study was conducted to examine the 
association between smoking and disease risk in MS cases (n=26) and controls (n=26).  Disease 
severity within MS patients was assessed through clinical and radiological outcomes.  These 
measures were confirmed within a larger dataset of MS patients (n=512) that additionally 
contained genotyping information.  There were no significant differences in disease risk or 
severity in the pilot study.  Within the larger dataset, clinical score trended toward significance 
(p=0.13).  Stratification based on HLA DRB1*1501 status showed that MS smokers with the 
HLA DRB1*1501 allele had 2.86 greater odds of having more severe clinical disease than 
nonsmokers with the genotype (1.41, 5.80; p=0.003).  To our knowledge, this is the first study to 
examine smoking and MS disease severity while controlling for genotype.  
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INTRODUCTION  
 Multiple sclerosis (MS) affects over 400,000 Americans and 2.5 million people 
worldwide, and is the most common neurological disease in young adults.1,2  Multiple sclerosis is 
characterized as an immune-mediated demyelinating disorder resulting in significant disability 
and decreased quality of life.  While several genome-wide linkage studies have confirmed a 
strong genetic component of disease inheritance of MS with risk among family members up to 
50 times higher than on average in the population,3,4 MS is also thought to involve environmental 
factors which may be crucial to disease development.5  For example, a study examining MS in 
the Australian population has attributed modifiable environmental factors in being able to 
prevent approximately 80% of cases.6 
 Large-scale prospective epidemiological studies of MS have been limited in number and 
generally lack the statistical power to detect an association due to the relatively rare status of the 
disease, which affects 3.6 cases per 100,000 person-years in women, and 2.0 cases per 100,000 
person-years in men.7  Despite the paucity of epidemiological research, historical and 
prospective cohort studies, as well as case-control designed experiments, have consistently 
identified three main environmental factors associated with risk of MS: vitamin D deficiency 
(and/or sun exposure), cigarette smoking, and infection with Epstein Barr virus.6,8,9  Other 
possible agents include, but are not limited to: duration of breastfeeding,10,11 diet,12-15 obesity,16 
oral contraceptive use,17,18 history of allergy,19,20 and air pollution.21 
 These environmental studies, however, have largely been observational in nature and 
dependent on previously collected data, which has resulted in limited conclusive findings.  
Furthermore, studies examining MS risk factors have also lacked objective measures, relying 
primarily on subjective outcomes of physical functioning and routine assessments that are 
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conducted in the clinic, such as the Timed 25-Foot Walk22 and Kurtze’s Expanded Disability 
Status Scale (EDSS),23 respectively.  This has made it difficult to characterize the various disease 
subtypes that exist, both clinically and pathologically, and to follow disease progression, 
severity, and responses to therapy.8 
 Therefore, there exists a critical need for longitudinal data collection of environmental 
risk factors to investigate how these types of exposures may influence certain disease 
characteristics and relate to clinical, immunological, radiological, and genetic markers.  This will 
lead to a better understanding of MS etiology, with the potential to improve treatment and 
eventually lead to primary preventative measures that will assist in reducing the risk of MS in the 
population.  
 The Multiple Sclerosis Center at Yale University in New Haven, CT will be undertaking 
a large cohort study with the intent to examine a multitude of risk factors in MS.  Currently, the 
Yale MS Center treats over 1,000 patients annually from the greater southern Connecticut area. 
The Center offers state-of-the-art treatment for patients with MS and demyelinating-related 
diseases, and is focused on providing the best patient care available, while also being active in 
clinical research and public health initiatives.  The multidisciplinary team is involved in many 
ongoing clinical trials with highly experienced personnel aiming to advance the understanding of 
MS and improve treatment options and quality of life for its patients. 
 The aim of the Yale MS Center cohort study is to build a quantitative risk assessment 
model by combining genetic, immunological, radiological, clinical and epidemiological 
measures in attempt to better assess MS disease risk, characterize disease severity, and measure 
disease progression over time.  One important aspect of the study was to create a questionnaire 
that would allow for the collection of retrospective and prospective epidemiological data to 
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capture information on various environmental risk factors.  These measures would assist in 
determining how these exposures relate to MS disease alone, as well as in conjunction with other 
covariates, such as specific genotypes and serum biomarkers.  
 
Development of the Questionnaire 
 In order document patients’ histories with respect to a variety of environmental 
exposures, the Social and Environmental Questionnaire (SEQ) was designed by the primary 
investigator (see Appendix A).  While there have been a variety of exposures studied in relation 
to MS, those that were selected for the questionnaire were either previously found to be strongly 
associated with MS or thought to have suffered from measurement issues  (i.e. inconsistent or 
imprecise measurement), and thus were included in an attempt to be more accurately assessed. 
Additionally, the questionnaire highlights areas of recent importance to the immunologists and 
other researchers working with the Yale MS Center in order to investigate their specific 
hypotheses.  
   What differs in this questionnaire compared to previous studies of MS is that 
investigators were interested in measuring not only the duration of environmental exposure, but 
also the severity or intensity of each exposure.  The investigators also sought a more 
comprehensive measure of environmental exposures, which is often not accounted for in MS 
research.  By looking at a number of variables in a large cohort, the group will be able to 
measure interaction effects between environmental risk factors, as well as in conjunction with 
imaging measures, immunologic biomarkers, and genetic factors. 
 The SEQ represents one portion of the data collection in this cohort study that will 
examine a multitude of risk factors through recruitment of cases from the Yale MS Center and 
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matched controls from the greater Connecticut area, both of which will be followed over a five-
year period.  Two versions of the SEQ were developed for both cases and controls: a baseline 
questionnaire, and a follow-up questionnaire.  The baseline questionnaire includes questions 
relating to childhood and recent exposures, while the follow-up questionnaire focuses on the 
domains in relation to ‘time since last visit,’ with the intent to be administered at each follow-up 
research visit over the course of five years.  
 The baseline SEQ includes seven domains: 1) childhood environment; 2) sun exposure; 
3) tobacco exposure (active and passive); 4) physical activity; 5) diet (childhood and current); 6) 
oral contraceptives; and 7) social demographics.  The measures for each domain were derived 
from a variety of sources.  In most instances, the domains were either not previously studied in 
MS or not well tested, and therefore the standardized questions were derived from studies 
examining other diseased populations.  
 In order to establish any areas of concern or problematic features of the questionnaire, the 
SEQ was pilot tested in both MS cases (N=26) and controls (N=26).  Despite the sample size, the 
goal of the pilot study was to identify large associations and/or generate hypotheses that could be 
later tested and confirmed in the longitudinal study.  Analysis of the cohort’s baseline data will 
also allow investigators to verify whether results from the cross-sectional analysis are consistent 
with subsequent analyses of longitudinal data over time.  Lastly, the data will enable the group to 
assess disease progression over time, matching subjective clinical measures with objective 
measures, such as changes measured by MRI. 
 Due to the small sample size of the pilot study, one domain was investigated in relation to 
disease risk and severity: tobacco exposure.  Smoking has been cited as one of the leading 
modifiable environmental risk factors in MS; however, previous studies have suffered from 
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inconsistent measurement and inadequate adjustment of potentially important covariates. The 
SEQ provides researchers with a more detailed method of measuring tobacco exposure by 
inquiring about both first and second hand smoking, as well as allowing participants to specify 
during which age periods the exposure occurred. 
 We hypothesize that there will be significant differences between MS cases and controls 
with respect to smoking status. MS cases will be significantly more likely to have smoked and 
have been exposed to second hand smoke than control subjects. Additionally, MS cases that have 
smoked will have more severe clinical and radiological outcomes than MS never smokers.  
 
Measuring Tobacco Exposure 
 Tobacco smoking is one of the most prominent risk factors related to a multitude of 
chronic diseases, especially those related to the respiratory tract and the cardiovascular system.24 
Smoking has also been associated with many immune-mediated diseases, thought to result from 
persistent exposure to chemicals that can indirectly cause oxidative stress and inflammation 
responses throughout the body, while also placing individuals at an increased risk of infection.25 
 Although the exact mechanism is still unknown, smoking and nicotine exposure are 
thought to act on the immune system through both pro-inflammatory and immunosuppressive 
mechanisms.  Epidemiologic studies examining the effects of smoking and autoimmune diseases 
have consistently found associations with patients suffering from rheumatoid arthritis,26-28 
systemic lupus erythematous, 29,30 Graves’ disease,31,32 and primary biliary cirrhosis.33  
 Previous studies examining tobacco exposure in MS patients have used a variety of 
methods to assess its contribution to disease risk.  Despite this heterogeneity, a recent meta-
analysis found a significant association between smoking and risk of MS by combining 
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information from six case-control studies and three prospective cohorts (RR 1.5 [1.4-1.7]).34  The 
authors stated that although the relative risk was somewhat small, consistent findings strongly 
argue for a causal association.   
 A number of studies have also investigated how smoking may influence MS disease 
course.  Results from these studies demonstrated negative effects on various clinical measures, 
such as the Kurtze’s Expanded Disability Status Scale (EDSS),23 as well as T1 and T2 volume 
lesion load, representative of subclinical disease activity.35,36  Additionally, smoking has been 
associated with faster progression to more severe types of MS (e.g. clinically-isolated syndrome 
to relapsing-remitting MS, and relapsing remitting MS to secondary-progressive MS), further 
implicating smoking as a leading environmental risk factor for disease severity in MS.35,37,38 
However, these studies were only able to identify a risk between ever smokers compared to 
never smokers, and did not find an association with increasing pack-years. 
 While first hand smoking has been well studied with respect to MS risk, there have only 
been three published studies examining the association between second hand smoke and disease 
onset.  A French case-control study found an adjusted relative risk of 2.12 [95% confidence 
interval 1.43-3.15] in children diagnosed with MS associated with parental smoke exposure,39 
while another study found no association between maternal smoking during pregnancy and risk 
of MS.40  Most recently, Hedstrom et al. (2011) looked at the effect of second hand smoking in a 
Swedish cohort of MS patients that identified themselves as never smokers.41  The group found a 
small, yet significant association (OR 1.3 [95% confidence interval 1.1-1.6]) and demonstrated 
an increase in risk with increased exposure (p-value for trend = 0.008), even after controlling for 
a number of covariates (EBV infection, vitamin D status, ultraviolet radiation, and heredity). 
Furthermore, the authors found that when second hand smoke persisted for a duration of 20 years 
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or longer, the OR increased to 1.8 [95% confidence interval 1.2-2.6].  However, the study did not 
examine if certain time periods, such as childhood versus late adolescence, made individuals 
more susceptible to disease. 
 It may be that smoking explains only a small component of MS risk; however, one might 
argue that previous measures have suffered from inexact or inconsistent measurement analysis. 
A recent review in the MS literature cited the difficulty in conducting meta-analyses of smoking 
and MS risk due to the heterogeneity in how data has been collected across studies (e.g. 
‘cigarettes per day,’ ‘pack-years,’ etc.). 34  In general, previous studies have estimated smoking 
by ‘pack-years,’ a single number which is meant to represent an individuals’ entire smoking 
history.  This value, however, may not capture changes in smoking habits throughout time, nor 
be an accurate reflection of intensity and frequency of smoking. 
 In order to resolve this issue, the SEQ was designed to include a number of questions that 
attempt to measure smoking history in more detail.  The questionnaire begins as most other 
smoking assessments do in current literature with the primary question: “Do you or did you ever 
smoke cigarettes, that means smoked at least 100 cigarettes in your lifetime?,” with ‘Yes’ or 
‘No’ as options available to respondents.  Those that check “no” are asked to skip the section and 
move on. Those that check “yes” are prompted with the next question: “About how many packs, 
on average, did you smoke per day? Fill in the blanks for as many of the following as 
necessary”: 
   1/2 pack a day (or less) for ______ years 
   1 pack a day for ______ years 
   1.5 packs a day for _____ years 
   2 or more packs a day for _____ years 
 By allowing respondents to answer in multiple fields, the questionnaire does not force 
participants to give a single approximation of smoking, which may be the source of imprecise 
Milena Gianfrancesco 
 
14 
measurement in past literature.  The creation of a more detailed method attempts to solve this 
issue by minimizing the potential for inaccurate measurement by providing researchers with a 
better estimate of smoking history.  
 The next question asks participants “How old were you when you first started smoking?” 
in order to measure any association between age at which one begins smoking and disease risk. 
Additionally, subjects are asked about their current smoking habits: “Are you currently 
smoking?; If no, how many years ago did you quit?; How many years total have you smoked, not 
including any time that you may have quit smoking?”   
 Given the recent findings that second hand smoking may have a role in disease risk, the 
SEQ also includes questions regarding passive exposure to tobacco.  The SEQ utilizes the 
questionnaire used by Hedstrom et al.41 since it provides researchers with a tool that has been 
validated in the MS population.  This questionnaire asks participants: “Have you ever lived with 
one or more people that used to smoke indoors or outdoors on a daily basis?” and “At your work, 
have you on a daily basis spent time in rooms/spaces where people smoke?”  Participants are 
also asked to specify the estimated duration (in years) of exposure.  
 In addition to the Hedstrom et al. questions mentioned above, the SEQ goes into further 
detail regarding the timing of exposure to environmental smoke.  We asked participants to 
indicate not only how long the exposure occurred (years), but also for an approximate number of 
hours/day they were exposed to second hand smoke.  Moreover, since previous studies have 
implicated that smoking may play more of a role during earlier stages of life, we determined that 
it would be important to record the periods in which exposure occurred. 
If yes, please specify for each category: 
a) Young Child, 0-10 years of age: 
____________ hours a day for _________ years 
b) Adolescent/Teen, 11-20 years of age 
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____________ hours a day for _________ years 
c) Adult, 21+ years of age 
____________ hours a day for _________ years 
 By including more detailed questions regarding exposure during specific periods of life, 
we can attempt to measure if disease risk is more susceptible during certain age periods (i.e. 
windows of exposure), as has been found with MS and other environmental risk factors, such as 
sun exposure.42  
 Important to note is that none of the aforementioned studies examining smoking and MS 
appropriately controlled for genotype, specifically HLA1 DRB1*1501, which has been cited in 
literature to be associated with MS disease susceptibility.43-45  Individuals that carry one or more 
copies of this allele have been shown to have an increased number of white matter lesions and a 
reduction in normalized brain parenchymal volume, as well as significant cognitive 
impairments.36,46  Since this allele is also associated with having a higher disease burden, both 
clinically and radiologically, it would be critical to control for this factor in order to better 
measure how smoking influences MS disease risk and severity.  
 To date, only one study has examined how genetics interplay with the smoking-MS 
relationship.47  This group of researchers found a significant interaction between two genetic 
features in MS smokers, presence of HLA DRB1*15 (any allele carriage) and absence of HLA 
A*02.  Smokers with both factors were found to have a 13.5 (95% confidence interval 8.1, 22.6) 
times higher odds of developing MS compared to never smokers without the two factors, while 
smokers without both genetic features only had 1.4 (95% confidence interval 0.9, 2.1) odds of 
developing MS.  The study, however, only looked at disease risk and did not measure disease 
severity in relation to genotype and smoking status.  
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 While these findings further support the role of smoking and risk of MS in conjunction 
with genetic factors, they also underline the need to explore additional gene-environment 
interactions, as they are crucial to understanding the etiology of MS.  The SEQ, as a piece within 
the larger context of the five-year cohort study, will assist in establishing the role of various 
environmental factors in relation to more objective clinical and radiological outcomes, while also 
incorporating genetic susceptibility.  
 In order to explore the utility of the SEQ in measuring environmental risk factors, a pilot 
study was conducted within a small set of patients at the Yale MS Center. We examined the 
association between smoking status and disease risk in MS cases and frequency age and sex 
matched controls. We also studied the relationship between smoking and measures of disease 
severity in MS cases, assessed through both clinical and radiological outcomes. These measures 
were then confirmed within a larger dataset of MS patients, as there will be more power to detect 
an effect on severity in this dataset compared to the pilot dataset. The larger dataset also contains 
previous genotyping information at the HLA DRB1 locus, and will additionally allow us to 
examine whether the effects of smoking on MS severity are modified by HLA DRB1 status.  
 
METHODS 
Participants 
 Pilot dataset: The primary investigator personally approached all MS patients before or 
after their scheduled appointments at the Yale Multiple Sclerosis Center during the fall of 2011. 
Eligible participants were defined as: MS patients aged 18-70 years with a confirmed diagnosis 
of MS by a neurologist based on the International Panel criteria;48,49 willingness to participate; 
and an ability to comprehend the instructions of the questionnaire.  Out of the 39 MS patients 
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that were approached, 26 completed the questionnaire [recruitment rate = 64%].  Control 
subjects consisted of healthy individuals in the greater CT area without a diagnosis of MS or 
other demyelinating disease, between the ages 18-70 years, frequency matched to cases based on 
sex and age (+ 5 years).  All participants signed an informed consent and the study was approved 
by the Yale HIC Committee (HIC#1103008246). 
 Confirmatory dataset: The confirmatory dataset was available to the primary 
investigator from Dr. Daniel Pelletier, Division Chief of the Yale Multiple Sclerosis Clinic, 
formally at the University of California San Francisco (UCSF) Multiple Sclerosis Center. The 
dataset included information collected from a five-year cohort study of MS patients (n=577) 
primarily from the UCSF MS Center, in which individuals aged 18-70 with a confirmed 
diagnosis of MS were recruited to participate.50  The study was approved by the UCSF 
Committee on Human Research. 
 
Exposure Measurement 
 Pilot study participants were asked to complete a Social and Environmental 
Questionnaire (SEQ) comprised of sixty-nine items covering the following domains: 1) 
Childhood Environment; 2) Sun Exposure; 3) Tobacco Exposure (Active and Passive); 4) 
Physical Activity; 5) Diet (Childhood and Current); 6) Oral Contraceptives; and 7) Social 
Demographics (see Appendix A).  
 First hand smoking in the pilot study was assessed by asking participants if they had 
smoked at least 100 cigarettes in their lifetime (ever/never), and further inquiring about the 
number of packs/day over time (cumulative pack-years).  Second hand smoking was measured 
by asking participants if they have ever lived or worked with one or more people that used to 
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smoke indoors or outdoors on a daily basis.41  Participants also specified the estimated hours/day 
and duration (in years) of exposure, as well as specific age periods during which the exposure 
occurred. 
 The confirmatory dataset included information on whether patients were never, current, 
or former smokers.  For subsequent analyses, current and former smokers were categorized as 
‘ever’ smokers.  
 
Outcome Measurement 
 In the pilot study, the outcome of disease was determined by an individual’s status as 
case or control participant as determined by the eligibility criteria mentioned above.  Severity of 
MS disease was assessed by both clinic measure and magnetic resonance imaging (MRI). 
Clinical severity was determined by Kurtze’s Expanded Disability Status Scale (EDSS)23 scores 
obtained in the clinic at the patient’s time of visit at which they completed the questionnaire. 
Clinical EDSS score was represented as a binary variable, divided by scores less than 3.0 
(minimal disability) to scores equal to or greater than 3.0 (moderate to severe disability).  An 
EDSS score of 3.0 has been consistently used in MS literature as a defined parameter in clinical 
trials and studies examining disease course and prognosis.51-53  MRI scans of MS cases in the 
pilot study were identified at a date closest to questionnaire and EDSS assessment, preferably 
within a six-month period.  An MS neurologist (DP) blinded to outcome and exposure variables 
read the brain images and recorded the number of white matter lesions as assessed by T2-
weighted brain MRI scans, which were then divided into categories (0-9 = mild; 10-19 = 
moderate; 20+ = severe). 
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 The confirmatory dataset included EDSS scores obtained in the clinic and MRI brain 
scans at the patient’s baseline assessment visit.  The number of gadolinium contrast-enhancing 
(CE) lesions (a measure of acute inflammatory MS activity) and T2-weighted lesion volume 
(mm3) (a measure of overall white matter disease burden) was recorded using axial dual-echo 
T2/PD-weighted images.50   
 
Statistical Analysis 
 Due to the small sample size, non-parametric tests of association were performed for the 
pilot dataset.  Demographic differences between cases and controls in the pilot study were 
compared using Fisher’s exact test and Mann-Whitney U test where appropriate.  Differences 
between MS patients in the pilot study and MS patients in the confirmatory dataset were 
analyzed using X2 test and independent sample t-test where appropriate. 
 For the pilot study, logistic regression was applied to calculate the odds ratio for the risk 
of having an MS diagnosis in participants who reported ever and never smoking with a 95% 
confidence interval.  A subset analysis of only smokers was also conducted, with number of 
pack-years as the primary predictor of risk of MS.  Pack-years was a binary variable, divided as 
greater/equal or less than 16 pack-years, as measured in a previous study of MS.54  The primary 
predictor for each model was the smoking variable (ever/never; pack-years > or < 16), adjusted 
for age.  
 Disease severity outcomes in the pilot dataset of MS patients included EDSS score (> or 
< 3) as the clinical dependent variable and number of T2 lesions (mild vs. moderate/severe) as 
the MRI dependent variable, using separate logistic regression models. The primary predictor of 
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each model was smoking status (ever/never), adjusted for age and disease duration.  Due to the 
small sample size, all data for the pilot study were determined significant if p < 0.05.  
 In the confirmatory dataset, MS severity outcomes included EDSS score (> or < 3) as the 
clinical dependent variable using a logistic regression model, and T2-weighted lesion volume 
(mm3) by conducting a linear regression model.  T2-weighted lesion volume was log-
transformed in order to reflect a more normal distribution.35  Number of gadolinium contrast-
enhancing lesions also served as an MRI outcome and was analyzed using Poisson log-linear 
regression approach, as previously done in MS literature.36,55  The primary predictor of each 
model was smoking status (ever/never), adjusted for age, sex, disease duration, and HLA DRB1 
status (positive or negative for the *15:01 allele; at least one copy was considered positive).46 
Interaction variables were also created to test the multiplicative effect of smoking and HLA 
DRB1 status on disease severity outcomes in this dataset.  All data for the confirmatory dataset 
analyses were determined significant if p < 0.01.  
 
RESULTS 
Demographics 
 Table 1 describes demographic and disease characteristics of pilot and confirmatory 
dataset participants.  The pilot study included 26 MS cases and 26 frequency age and sex 
matched controls.  The mean age of MS cases in the pilot study was 47.1 + 9.4 years, and 48.5 + 
9.9 year for controls (p=0.28).  There were an equal number of females (n=22) and males (n=4) 
in each group (p=1.00).  
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 The confirmatory dataset was compromised of 577 MS patients.  Of these, 512 had both 
smoking and genotype baseline information on file.  Among the 512 MS patients, 68.75% were 
female (n=352) and 31.25% were male (n=160).  
 Compared to the confirmatory dataset, MS patients in the pilot study were older (p=0.03) 
and had a higher ratio of men to women (p=0.09).  MS patients in the pilot study also had a 
shorter disease duration (6.1 + 6.4 vs. 9.2 + 9.0; p=0.09), higher EDSS (2.6 + 2.0 vs. 2.0 + 1.6; 
p=0.07), and were also more likely to have smoked (p=0.03) compared to patients in the 
confirmatory dataset. However, these values were not significant at alpha = 0.01 level. 
 
MS Susceptibility 
 A slightly higher percentage of MS patients in the pilot study were smokers compared to 
controls (65.4% vs. 57.7%), but results were not significant (p=0.78).  MS patients that identified 
themselves as ever smokers also had a higher mean number of average pack-years compared to 
controls (13.4 + 12.7 vs. 9.8 + 7.5), but these results were not significant (p=0.63).  Compared to 
control participants, MS cases were not more likely to have lived with a smoker during their 
lifetime (p=0.76), or during specified age periods (childhood, p=0.40; teenage years, p=0.39) 
(Table 1).  
 Ever smokers had increased odds of having a diagnosis of MS compared to never 
smokers, but this was not significant (OR 1.38 [95% confidence interval 0.45, 4.25]; p=0.57). 
After adjusting for age, smokers had 1.21 higher odds of developing MS (95% confidence 
interval 0.38, 3.90) compared to never smokers, but results were not significant (p=0.75).  In a 
sub-analysis of only smokers (n=32), those with 16 or more pack-years had 1.50 odds of having 
an MS diagnosis, but this was not significant (95% confidence interval 0.33, 6.83; p=0.60).  
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When adjusted for age, the odds increased to 1.65, but this was also not significant (95% 
confidence interval 0.32, 7.66; p=0.58) (Table 2). 
 
MS Severity 
 There were no significant differences between MS ever and MS never smokers with 
respect to age and disease duration in the pilot study (n=26; p=0.17 and p=0.95, respectively).  
There were also no significant differences between MS ever smokers and MS never smokers 
with respect to T2 lesion category (n=21; OR 3.71 [95% confidence interval 0.42,33.1]; p=0.24) 
and EDSS score (n=24; OR 0.16 [95% confidence interval 0.02, 1.53]; p=0.11) (Table 3). Two 
of the 26 MS patients did not have an EDSS score reported within six-months of questionnaire 
assessment, and 5 of the 26 MS patients did not have MRIs within the specified time period. 
 Within the confirmatory dataset of MS patients, there were no differences between ever 
and never smokers with respect to age (p=0.25), sex (p=0.18), disease duration (p=0.48), and 
genotype status (p=0.94).  Unadjusted analyses reflected no significant differences in outcome 
measures between ever and never MS smokers (p=0.56 for number of CE lesions; p=0.74 for T2 
lesion volume; p=0.06 for clinical EDSS score).  In the adjusted analysis, there were no 
significant differences in MRI measures between ever and never MS smokers (p=0.40 for 
number of CE lesions; p=0.58 for T2 lesion volume).  MS ever smokers had 1.39 odds of having 
an EDSS of 3.0 or greater, however this was not significant (95% confidence interval 0.90, 2.13; 
p=0.13) (Table 4).  
 Analysis did not show an interaction effect between genotype and smoking in relation to 
number of CE Lesions (p=0.70) or T2 lesion volume (p=0.46).  There was, however, a 
significant interaction effect between genotype and smoking status with respect to clinical EDSS 
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categorization (p=0.01), thus the data were stratified by HLA DRB1*1501 status.  Upon 
stratification by genotype, MS smokers carrying at least one copy of the HLA DRB1*1501 allele 
were significantly 2.86 times more likely to have an EDSS score > 3 than never smokers with the 
allele (95% confidence interval 1.46, 5.80; p=0.003).  There was no significant difference in 
EDSS score between MS ever and MS never smokers without the HLA DRB1 allele (OR 0.89 
[95% confidence interval 0.50, 1.56]; p=0.68) (Table 5).  
 
DISCUSSION 
 The purpose of this pilot study was to explore the relationship between smoking and MS 
disease risk, as well as disease severity.  While previous studies have shown an association with 
ever/never smoking, the relationship with respect to number of pack-years smoked is less clear.  
By allowing patients to more accurately specify the number of packs-per-day throughout their 
smoking history, the SEQ attempted to capture information that may not have historically been 
recorded in previous studies.  Furthermore, the pilot study utilized clinical (EDSS) as well as 
radiologic (MRI) outcomes to measure disease severity.  In addition to first hand smoking, the 
SEQ captures information on second hand smoke exposure throughout various periods of one’s 
life, which also may be important in determining disease risk and severity.  
 Compared to previous studies examining smoking and MS disease susceptibility, our 
pilot study did not find an association between ever smoking and risk of MS.  Though we found 
that slightly more MS patients were smokers compared to controls, these results were not 
significant.  In a subgroup analysis of only smokers, pack-years seemed to better predict disease 
risk in the adjusted model, though results were also not significant.  MS cases were not more 
likely to have ever lived with a smoker, nor more likely to have been exposed to second hand 
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smoke during childhood or teenage years.  There were also no significant differences between 
MS ever smokers and MS never smokers with respect to categorical T2 lesion count and EDSS 
score.   
 The lack of significant findings in relation to disease susceptibility is most likely due to 
low power.  A power analysis indicated that in order to detect an association with 80% power at 
an alpha level of 0.05, at least 310 individuals per case and control group would be needed, 
assuming an effect size of 1.5.34   An ongoing cohort study based out of the Yale MS Center with 
a larger sample size will be able to better determine whether our measure of pack-years allows 
for a more specific and sensitive assessment of MS disease risk.   
 Results from the pilot study were strengthened by the ability to compare findings of 
disease severity within a larger confirmatory dataset of MS patients.  This second dataset made it 
possible for us to control for genetic factors that may play a role in influencing disease severity. 
While we did not find a significant association between smoking and MRI measures in this 
dataset, we did find an association that trended toward significance with respect to clinical EDSS 
score after controlling for important covariates.  Detection of an interaction effect between 
smoking and genotype led us to stratify analyses based on HLA DRB1*1501 status.  These 
results showed a striking difference for disease severity between MS patients carrying at least 
one copy of the allele and MS patients that did not.  MS ever smokers positive for HLA 
DRB1*1501 were 2.86 times more likely to have an EDSS score of 3 or higher than MS patients 
with the allele that never smoked.  Among MS patients without the allele, there was no 
difference between ever smokers and never smokers in relation to clinical disease severity.  
 To our knowledge, this is the first study to examine the influence of smoking on MS 
disease severity while also controlling for genetic factors.  A previous study found an association 
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between smoking and HLA DRB1 status and risk for MS, but did not look at how these factors 
affected clinical or radiological outcomes.47  It is interesting that although we detected an 
association between smoking and clinical measure (EDSS) based on genotype, this was not true 
for MRI measures.  This is contrary to a previous study that found associations between smoking 
and MS severity as measured by contrast enhancing lesions, as well as T1 and T2 volume load; 
however, this study did not control for genetic factors.36  Our results suggest that there are 
differential effects of smoking on MS severity by genotype as measured by EDSS, and while we 
did not find this to be true for MRI measures, future studies should incorporate genotype status 
in their analyses as it may modify results.  Repeated studies adjusting for genotype will be able 
to determine if our findings are valid in other populations. 
 There are several hypotheses as to why we may not have seen an association between 
MRI outcomes and smoking status.  EDSS measures are largely based on functional and walking 
ability, which may reflect lesions in the spinal cord rather than the brain.  Therefore, a 
correlation between MRI measures of the brain and smoking would not be detectable using our 
methods, but would be measurable using EDSS scores.  Future studies should consider 
examining both brain and spinal cord lesions as an outcome measure in relation to smoking, and 
measure how this compares to measurement using EDSS scores.  Additionally, our MRI analyses 
used only measures of white matter lesions (T2-weighted scans), and not gray matter lesions, 
which may result in different findings. 
 Though there is substantial evidence to suggest a role for both first and second hand 
smoke in MS disease risk, the biological mechanism through which this occurs is still 
unclear.56,57  It may be the chemical components of cigarette smoke and not tobacco itself, as a 
population-based study of MS examining tobacco snuff use did not detect an association.58  
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There are over 4500 potential chemical factors in cigarette smoke that could be responsible for 
mediating disease activity.27  Two current candidates of interest include cyanide and nitric oxide.  
Increasing doses of these chemicals have been associated with demyelination in the CNS of 
animals59,60 and found to induce axonal loss.61  Previous studies exposing smoke to animal 
models of MS (experimental autoimmune encephalomyelitis mice) suggest a mechanism via the 
immune system, specifically with B- and T-lymphocytes and natural killer cells.24,62,63  
 Cigarette smoke has been associated with a number of autoimmune diseases, such as 
rheumatoid arthritis,26-28 systemic lupus erythematous, 29,30 Graves’ disease,31,32 and primary 
biliary cirrhosis.33  Furthermore, it has been shown that HLA genes interact with smoking status 
to increase the risk of rheumatoid arthritis,64 as well as MS.47  Therefore, it is hypothesized that 
these genes, which have a role in presenting peptides to T cells, trigger post-translational 
modification of peptides cross-reactive with CNS antigens, thus stimulating autoimmunity 
against the central nervous system.47  
 Other hypotheses linking smoking to MS risk include the possibility of increased risk of 
infection (e.g. Epstein-Barr virus or other respiratory infection) or influence on estrogen levels, 
thus disrupting the immune system balance via inflammation.65,66  Previous research has also 
indicated that nicotine can have a direct effect on blood-brain barrier functioning, which serves 
to protect the brain from passage of substances from blood into the central nervous system.67 
This site has been shown to be particularly susceptible in MS patients, as it is thought that one of 
the first events in MS pathogenesis is the passage of autoreactive T-cells across the blood-brain 
barrier.68,69  It will be important for future studies to examine how these and other environmental 
risk factors interact in predicting MS disease risk.  For example, smokers have been found to 
have lower serum concentrations of 25(OH) vitamin D and 1,25 (OH) vitamin D than non- 
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smokers,70 alluding to a possible link between these two well-known risk factors in MS patients.  
While a smoking-vitamin D concentration interaction has been found in studies examining 
rheumatoid arthritis patients,71 this hypothesis has yet to be explored in the MS population.57,72  
 There were several limitations to the pilot study.  Firstly, the sample size was not large 
enough for us to detect an association with enough power.  Due to the small sample size, we 
were also not able to control for disease subtype.  Future studies should examine whether there 
are differential effects of smoking on disease risk and severity depending on one’s subtype of 
MS.  We also did not have genetic information in our pilot sample, which our confirmatory 
analyses showed to be an important covariate to include in statistical models examining smoking 
in MS.  Furthermore, we did not have information on EBV infection or vitamin D status, both of 
which may serve as mediators or moderators to disease risk and severity.  
 There also is the possibility that other potential confounders that were not measured in 
the study track with smoking and may result in detection of an increased risk for disease (i.e. 
health behaviors such as diet, alcohol consumption, and low exposure to sunlight).  We cannot 
rule out the possibility that recall bias and/or selection bias may have influenced results in both 
cases and controls.  Participants also may have misreported smoking behaviors (social 
desirability bias); however, since participants answered questions in relation to a number of 
environmental factors and were not aware of the specific nature of this study (i.e. tobacco 
smoking), we believe that there was not a differential misreporting of smoking history in cases 
more than controls.  We also did not consider changes in cigarette manufacturing over time, such 
as tar content and filters.  Lastly, we were unable to assess second hand smoking in never 
smokers in our pilot study due to the small sample size.  Unfortunately, second hand smoking 
information was not collected in the larger confirmatory dataset.  Future studies should examine 
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the extent to which second hand smoke during certain age periods influences disease risk and 
severity while controlling for susceptible genotype.  This information would aid in identifying 
individuals who may be at increased risk not only through first hand, but also second hand 
smoking.   
 While results from the pilot study were not significant, they will assist in the creation of a 
more specific measure of environmental exposures in MS that will serve to improve 
epidemiological data collection in a future cohort study examining disease risk, severity, and 
progression. Results from the confirmatory dataset demonstrated an association between MS 
disease severity as measured by EDSS and smoking status when stratified by genotype.  These 
results will aid in formulating new hypotheses to be tested in the future with regards to genetic 
predisposition and risk of developing MS, as well as disease severity in relation to smoking 
status and other environmental risk factors.  
 This study has large public health relevance due to its epidemiological scope of which the 
field of MS is currently in critical need.  The Yale MS Center’s cohort study will be the first to 
appropriately examine environmental risk factors in conjunction with genetic, immunologic, 
clinical and radiologic measures to determine how they influence disease risk, severity, and 
progression over time.  It will also assist in determining how smoking may affect responses to 
treatment and various immunomodulatory therapies.69  The information gained from this study 
adds to literature by suggesting that gene-environment interactions may be associated with MS, 
and contributes to an improved understanding of the disease’s etiology and progression.  
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Table	  1.	  Demographic	  and	  disease	  characteristics	  of	  pilot	  and	  confirmatory	  study	  participantsa	  	  
	  
	  	   	   	   	   	  
Characteristic	  
MS	  –	  Pilot	  	  
(N	  =	  26)	  
Controls	  –	  Pilot	  
(N	  =	  26)	  
	  
Pb	  
MS	  –	  Confirmatory	  
(N=512)	  	   Pc	  
Age	  (years)	   47.1	  +	  9.4	   48.5	  +	  9.9	   0.28	   42.5	  +	  9.8	   0.03	  
Sex	   	   	   1.00	   	   0.09	  
	  	  	  	  	  Female	   22	  (84.6)	   22	  (84.6)	   	   352	  (68.8)	   	  
	  	  	  	  	  Male	   4	  (15.4)	   4	  (15.4)	   	   160	  (31.2)	   	  
Disease	  Duration	   6.1	  +	  6.4	   -­‐-­‐	   -­‐-­‐	   9.2	  +	  9.0	   0.09	  
EDSS	   2.6	  	  +	  2.0	   -­‐-­‐	   -­‐-­‐	   2.00	  +	  1.6	   0.07	  
Smoker	   	   	   0.78	   	   0.03	  
	  	  	  	  	  Never	   9	  (34.6)	   11	  (42.3)	   	   291	  (56.8)	   	  
	  	  	  	  	  Ever	   17	  (65.4)	   15	  (57.7)	   	   221	  (43.2)	   	  
Pack-­‐Years	  (smokers,	  n=32)	  	   13.4	  +	  12.7	   9.8	  +	  7.5	   0.63	   -­‐-­‐	   -­‐-­‐	  
Live	  with	  Smoker	  (n=50)	   	   	   0.76	   -­‐-­‐	   -­‐-­‐	  
	  	  	  	  	  Yes	   16	  (64.0)	   18	  (72.0)	   	   	   	  
	  	  	  	  	  No	   9	  (36.0)	   7	  (28.0)	   	   	   	  
Live	  with	  Smoker,	  Child	   	   	   0.40	   -­‐-­‐	   -­‐-­‐	  
	  	  	  	  	  Yes	   10	  (40.0)	   14	  (56.0)	   	   	   	  
	  	  	  	  	  No	   15	  (60.0)	   11	  (44.0)	   	   	   	  
Live	  with	  Smoker,	  Teen	   	   	   0.39	   -­‐-­‐	   -­‐-­‐	  
	  	  	  	  	  Yes	   8	  (32.0)	   12	  (48.0)	   	   	   	  
	  	  	  	  	  No	   17	  (68.0)	   13	  (52.0)	   	   	   	  
a	  Table	  values	  are	  mean	  ±	  SD	  for	  continuous	  variables	  and	  n	  (column	  %)	  for	  categorical	  variables.	  
b	  P-­‐value	  is	  for	  Mann-­‐Whitney	  U	  test	  (continuous	  variables)	  or	  Fisher’s	  exact	  test	  (categorical	  variables)	  between	  
	   MS	  vs.	  Controls,	  Pilot	  Study	  
c	  P-­‐value	  is	  for	  t-­‐test	  (continuous	  variables)	  or	  χ2	  test	  (categorical	  variables)	  between	  	  
	   MS	  Pilot	  Study	  vs.	  MS	  Confirmatory	  Dataset	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Table	  2.	  	  Bivariate	  associations	  between	  smoking	  and	  MS	  diagnosis,	  pilot	  study	  (N=52)	  
	  
Characteristic	   N	   %	  MS	  
Unadjusted	  OR	  
(95%	  CI)	  	  	  
p-­‐value	   Adjusted	  OR*	  
(95%	  CI)	  
p-­‐value	  
Smoking	  status	   	   	   	   0.57	   	   0.75	  
	  	  	  	  	  Never	   20	   45%	   1.00	   	   1.00	   	  
	  	  	  	  	  Ever	   32	   53%	   1.38	  (0.45,	  4.25)	   	   1.21	  (0.38,	  3.90)	   	  
Pack-­‐years	  (smokers)	   	   	   	   0.60	   	   0.58	  
	  	  	  	  	  <	  16	   22	   50%	   1.00	   	   1.00	   	  
	  	  	  	  	  >	  16	  	   10	   60%	   1.50	  (0.33,	  6.83)	   	   1.56	  (0.32,	  7.66)	   	  
	   	   	   	   	   	   	  
*Adjusted	  for	  age	  	  
 
 
	  	  
	  
	  
	  
	  
	   	  
Milena Gianfrancesco 
 
31 
Table	  3.	  Demographic	  and	  disease	  characteristics	  of	  MS	  patients	  by	  smoking	  status,	  pilot	  study	  (n=26)a	  	  
	  
	  
a	  Table	  values	  are	  mean	  ±	  SD	  for	  continuous	  variables	  and	  n	  (column	  %)	  for	  categorical	  variables.	  
b	  P-­‐value	  is	  for	  Mann	  Whitney	  U-­‐test	  (continuous	  variables)	  or	  Fisher’s	  exact	  (categorical	  variables),	  Unadjusted	  
c	  P-­‐value	  is	  for	  Mann	  Whitney	  U-­‐test	  (continuous	  variables)	  or	  Fisher’s	  exact	  test	  (categorical	  variables),	  Adjusted	  
	   for	  age	  and	  disease	  duration 
	  
 
	  	   	   Unadjusted	   Adjusted	  
Characteristic	   Never	  (N	  =	  9)	   Ever	  (N	  =	  17)	   Pb	   Pc	  
Age	  (years)	   49.8	  +	  10.0	   45.1	  +	  7.9	   0.17	   -­‐-­‐	  
Disease	  Duration	   5.5	  +	  5.1	   6.4	  +	  7.1	   0.95	   -­‐-­‐	  
	   	   	   	   	  
T2	  Lesion	  Load	  (n=21)	   	   	   0.36	   0.24	  
	  	  	  	  	  	  Mild	   5	   6	   	   	  
	  	  	  	  	  	  Moderate	  /	  Severe	   2	   8	   	   	  
Clinical	  Score	  (n=24)	   	   	   0.17	   0.11	  
	  	  	  	  	  	  EDSS	  <	  3	   4	   13	   	   	  
	  	  	  	  	  	  EDSS	  >	  3	   4	   3	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 Table	  4.	  Demographic	  and	  disease	  characteristics	  of	  MS	  patients	  by	  smoking	  status,	  confirmatory	  	  
	  	  	  dataset	  (n=512)a	  	  
	  
	  	   	   	   	  
Characteristic	   Never	  (N	  =	  291)	   Ever	  (N	  =	  221)	   Pb	   Pc	  
Age	  (years)	   42.0	  +	  9.2	   43.1	  +	  10.5	   0.25	   -­‐-­‐	  
Sex	   	   	   0.18	   -­‐-­‐	  
	  	  	  	  	  Female	   207	  (71.1)	   145	  (65.6)	   	   	  
	  	  	  	  	  Male	   84	  (28.9)	   76	  (34.4)	   	   	  
Disease	  Duration	   8.9	  +	  8.5	   9.5	  +	  9.5	   0.48	   -­‐-­‐	  
HLA	  DRB1	  1501	  	   	   	   0.94	   -­‐-­‐	  
	  	  	  	  	  	  0	   159	  (54.6)	   120	  (54.3)	   	   	  
	  	  	  	  	  	  1-­‐2	   132	  (45.4)	   101	  (45.7)	   	   	  
	   	   	   	   	  
Number	  CE	  Lesions	  	   0.32	  +	  1.05	   0.38	  +	  1.11	   0.56	   0.40	  
T2	  Lesion	  Volume	  (mm3)	   7556.1	  +	  12,286.4	   7922.9	  +	  14,858.7	   0.74	   0.58	  
Clinical	  Score	   	   	   0.06	   0.13	  
	  	  	  	  	  	  EDSS	  <	  3	   222	  (76.3)	   152	  (68.8)	   	   	  
	  	  	  	  	  	  EDSS	  >	  3	   69	  (23.7)	   69	  (31.2)	   	   	  
	   	   	   	   	  
a	  Table	  values	  are	  mean	  ±	  SD	  for	  continuous	  variables	  and	  n	  (column	  %)	  for	  categorical	  variables.	  
b	  P-­‐value	  is	  for	  t-­‐test	  (continuous	  variables)	  or	  χ2	  test	  (categorical	  variables);	  Unadjusted	  
c	  P-­‐value	  is	  for	  t-­‐test	  (continuous	  variables)	  or	  χ2	  test	  (categorical	  variables);	  Adjusted	  for	  age,	  sex,	  disease	  
	   duration,	  and	  genotype	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Table	  5.	  	  Bivariate	  associations	  between	  smoking	  and	  EDSS	  >	  3,	  confirmatory	  dataset	  (N=512)	  	  
	  
Characteristic	   N	   %	  EDSS	  >	  3	  
Adjusted	  OR	  
(95%	  CI)	  
p-­‐value	  
Smoking	  status*	   	   	   	   0.13	  
	  	  	  	  	  Never	   291	   23.7	   1.00	   	  
	  	  	  	  	  Ever	   221	   31.2	   1.39	  (0.90,	  2.13)	   	  
	   	   	   	   	  
HLA	  DRB1	  1501	  (0)	   279	   	   	   	  
Smoking	  status‡	   	   	   	   0.68	  
	  	  	  	  	  Never	   159	   29	   1.00	   	  
	  	  	  	  	  Ever	   120	   30	   0.89	  (0.50,	  1.56)	   	  
	   	   	   	   	  
HLA	  DRB1	  1501	  (1-­‐2)	   233	   	   	   	  
Smoking	  status‡	   	   	   	   0.003§	  
	  	  	  	  	  Never	   132	   17.4	   1.00	   	  
	  	  	  	  	  Ever	   101	   32.7	   2.86	  (1.41,	  5.80)	   	  
	   	   	   	   	  
*Adjusted	  for	  age,	  sex,	  disease	  duration,	  and	  genotype	  
‡Adjusted	  for	  age,	  sex,	  and	  disease	  duration	  
§	  Significant	  at	  alpha	  =	  0.01	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